Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RAPP Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RAPP Stock 12 Month Forecast
Average Price Target
$54.25
▲(75.85% Upside)
| Highest Price Target$80.00 | Average Price Target$54.25 | Lowest Price Target$40.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$34→$40
Buy
29.66%
Upside
Reiterated
12/09/25
JonesTrading
$50
Buy
62.07%
Upside
Reiterated
12/08/25
Promising Outlook for Rapport Therapeutics: Buy Rating Backed by RAP-219's Clinical Success and Strategic Growth PlansWe saw no reason for concern emerge from the presentations and remain confident in RAP-219's potential to achieve approval and see broad use in refractory focal onset epilepsy. RAPP plans to hold an end-of-Phase II meeting with the FDA in 4Q25 and initiate two Phase III pivotal trials in 3Q26. Rapport is also conducting an open-label long term safety trial, with preliminary data expected in 2H26. As a reminder, we estimate RAP-219 could generate risk-adjusted (50% probability of success [PoS]) net revenue of $2.847B in the U.S. and $212M in the E.U. + U.K. in refractory focal onset epilepsy by FY35 (the terminal year in our model). We reiterate our Buy rating and $50 price target.
BTIG
$47
Buy
52.35%
Upside
Initiated
12/02/25
Truist Financial
―
Buy
―
Reiterated
11/10/25
Citizens JMP
$77→$80
Buy
159.32%
Upside
Reiterated
11/07/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Goldman Sachs
$51
Buy
65.32%
Upside
Assigned
09/12/25
Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP)Post the positive Ph2 proof-of-concept data for RAP-219 in focal onset epilepsy (FOS), we assign a Buy rating to RAPP with a $51, 12-month price target, from the previous Early-Stage Biotech (ESB) designation.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$34→$40
Buy
29.66%
Upside
Reiterated
12/09/25
JonesTrading
$50
Buy
62.07%
Upside
Reiterated
12/08/25
Promising Outlook for Rapport Therapeutics: Buy Rating Backed by RAP-219's Clinical Success and Strategic Growth PlansWe saw no reason for concern emerge from the presentations and remain confident in RAP-219's potential to achieve approval and see broad use in refractory focal onset epilepsy. RAPP plans to hold an end-of-Phase II meeting with the FDA in 4Q25 and initiate two Phase III pivotal trials in 3Q26. Rapport is also conducting an open-label long term safety trial, with preliminary data expected in 2H26. As a reminder, we estimate RAP-219 could generate risk-adjusted (50% probability of success [PoS]) net revenue of $2.847B in the U.S. and $212M in the E.U. + U.K. in refractory focal onset epilepsy by FY35 (the terminal year in our model). We reiterate our Buy rating and $50 price target.
BTIG
$47
Buy
52.35%
Upside
Initiated
12/02/25
Truist Financial
―
Buy
―
Reiterated
11/10/25
Citizens JMP
$77→$80
Buy
159.32%
Upside
Reiterated
11/07/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Goldman Sachs
$51
Buy
65.32%
Upside
Assigned
09/12/25
Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP)Post the positive Ph2 proof-of-concept data for RAP-219 in focal onset epilepsy (FOS), we assign a Buy rating to RAPP with a $51, 12-month price target, from the previous Early-Stage Biotech (ESB) designation.
Best Analysts Covering Rapport Therapeutics, Inc.
1 Month
xxx
Success Rate
5/10 ratings generated profit
Average Return
+0.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.08% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
+10.65%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +10.65% per trade.
1 Year
Success Rate
8/11 ratings generated profit
Average Return
+77.91%
reiterated a buy rating 13 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +77.91% per trade.
2 Years
xxx
Success Rate
9/10 ratings generated profit
Average Return
+78.31%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +78.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RAPP Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Strong Buy
6
11
14
15
11
Buy
3
3
3
7
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
14
17
22
18
Each month's total comprises the sum of three months' worth of ratings.
RAPP Financial Forecast
RAPP Stock Forecast FAQ
What is RAPP’s average 12-month price target, according to analysts?
Based on analyst ratings, Rapport Therapeutics, Inc.’s 12-month average price target is 54.25.
What is RAPP’s upside potential, based on the analysts’ average price target?
Rapport Therapeutics, Inc. has 75.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RAPP a Buy, Sell or Hold?
Rapport Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Rapport Therapeutics, Inc.’s price target?
The average price target for Rapport Therapeutics, Inc. is 54.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $40.00. The average price target represents 75.85% Increase from the current price of $30.85.
The highest analyst price target is $80.00 ,the lowest forecast is $40.00. The average price target represents 75.85% Increase from the current price of $30.85.
What do analysts say about Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of RAPP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.